RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO
01 déc. 2023 12h32 HE
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. ANNOUNCES HIRING OF INTERIM CFO
Virender Ahluwalia will serve as Interim Chief Financial Officer
RetinalGeniX Technologies Inc. Appoints Stephen Tannenbaum to the Company's Business Advisory Board
28 nov. 2023 16h01 HE
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. APPOINTS STEPHEN TANNENBAUM
TO THE COMPANY'S BUSINESS ADVISORY BOARD. RetinalGeniX is an ophthalmic R&D company
RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs
09 nov. 2023 12h58 HE
|
RetinalGeniX Technologies, Inc.
RetinalGeniX Announces Therapeutic Solutions Being Developed for Dry Age-Related Macular Degeneration
and Alzheimer’s Syndrome.
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam™ Image Visualization Device
08 nov. 2023 05h45 HE
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC and AVANIA CRO CONTRACT to GUIDE the DEVELOPMENT of TWO DRUG THERAPIES and the RETINALCAM™ IMAGE VISUALIZATION DEVICE
Alkeus Pharmaceuticals Presents Positive Gildeuretinol Trial Results at American Academy of Ophthalmology, Demonstrating Significant Slowing of Retinal Atrophic Lesions in Stargardt Disease
03 nov. 2023 12h00 HE
|
Alkeus Pharmaceuticals
Primary endpoint met, demonstrating a 21% slowing (p<0.001) in the growth rate of atrophic retinal lesions compared to the untreated arm; 28% reduction (p<0.001) using observed atrophic...
RetinalGeniX IRB Approved to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
30 oct. 2023 14h51 HE
|
RetinalGeniX Technologies, Inc.
Proposed patient selection process is intended to reduce the cost and improve the safety and efficacy of patient candidate selection for ocular injections
Global Retinal Implant Market Anticipates Rapid Growth, Expected to Reach $112.2 Million by 2030
30 oct. 2023 11h18 HE
|
Research and Markets
Dublin, Oct. 30, 2023 (GLOBE NEWSWIRE) -- The "Retinal Implants Market Size, Share & Trends Analysis Report By Device Type (Retina Implant Alpha AMS, Implantable Miniature Telescope, Argus II),...
Global Pupillometer (Table-top, Hand-held) Market Size, Share & Trends Analysis Report 2023-2030
11 oct. 2023 06h58 HE
|
Research and Markets
Dublin, Oct. 11, 2023 (GLOBE NEWSWIRE) -- The "Pupillometer Market Size, Share & Trends Analysis Report By Mobility (Table-top, Hand-held), By Type (Video, Digital), By End Use (Hospitals, Eye...
Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China
04 oct. 2023 09h00 HE
|
Clearside Biomedical, Inc.
- Continued Progress in the Global Development and Commercialization of XIPERE® (known as ARCATUS® in China) - ALPHARETTA, Ga., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical,...
Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit
03 oct. 2023 16h35 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...